South Korea Biobanking Market Size, Share, Trends and Forecast by Specimen Type, Biobank Type, Application, End User, and Region, 2026-2034
The South Korea biobanking market size reached USD 1,288.9 Million in 2025 . Looking forward, the market is projected to reach USD 2,044.2 Million by 2034 , exhibiting a growth rate (CAGR) of 5.05% during 2026-2034 . The market is driven by government-led development of standardized biobank networks and capacity expansion. Growing demand from precision medicine and allied life-science R&D sectors is unlocking new commercial synergies. Technological advancements in automation, informatics, and data integration are further augmenting the South Korea biobanking market share.
SOUTH KOREA BIOBANKING MARKET TRENDS:
Nationwide Research Infrastructure and Policy-driven Expansion
South Korea has invested heavily in establishing nationwide biobanking networks linked to academic hospitals, research institutes, and public health agencies. These repositories store diverse biological samples, tissue, blood, and genomic data, supporting translational research, precision medicine, and drug discovery. On 28 th April 2025, the International Seabed Authority (ISA) and South Korea’s Ministry of Oceans and Fisheries signed a Letter of Cooperation during the 10th Our Ocean Conference in Busan, formalizing South Korea’s participation in the ISA Deep-Sea Biobank initiative. The initiative aims to expand global access to deep-sea biological samples and genetic data, with a focus on building research capacity, particularly for developing countries. This agreement positions South Korea as a central player in advancing marine biobanking and supports the nation’s broader strategy to lead in marine biotechnology and biodiversity conservation. The government has enacted policies mandating standardized bio-specimen collection, consent protocols, and data interoperability across institutions. Public-sector funding supports infrastructure upgrades, quality control systems, and secure IT platforms. As national projects integrate population-scale biobanks with clinical trial networks, demand for accredited sample storage and associated informatics services continues to expand. South Korea biobanking market growth is being propelled by these coordinated investments in infrastructure, professional training, and ethical governance, ensuring reliable, high-quality sample access for both local and international stakeholders.
Technological Integration and Data-Driven Expansion
The modern South Korean biobanking ecosystem is embracing automation, digital tracking, and integrated data platforms to enhance utility and scalability. Automated cold storage systems with remote environmental monitoring and backup power ensure sample integrity. Barcode and RFID systems synchronize physical sample movement with laboratory information management systems (LIMS), enabling audit trails and metadata capture. Advanced informatics platforms link biospecimen details with genomic, proteomic, and de-identified clinical data for AI-driven research. This integration supports cohort discovery, bioinformatics-driven stratification, and predictive modeling. Cybersecurity and privacy frameworks are embedded to comply with national data protection laws, enhancing trust among participants and stakeholders. As biobanks evolve from physical repositories to data-rich research assets, services such as sample processing, biomarker annotation, and analytics consulting are becoming profitable lines. On 9 th May 2024, CHA Bio Group and CIC signed an MoU to establish a Cell Gene Biobank-based Open Innovation Center (CGB) in Pangyo 2nd Techno Valley, South Korea. The facility, spanning 66,115 square meters across 14 floors, is scheduled for completion in December 2025 and will include CDMO production lines, cGMP manufacturing, and a stem cell biobank. This initiative is set to strengthen South Korea’s biobanking infrastructure by attracting biotech ventures and integrating clinical, academic, and industrial capabilities into one global biotech hub. Cross-institutional interoperability and cloud-based data sharing further strengthen collaborations, making the platform more attractive to multinational trials. The resulting digital-first transformation positions biobanks as essential infrastructure in South Korea’s bioscience innovation landscape.
SOUTH KOREA BIOBANKING MARKET SEGMENTATION:
IMARC Group provides an analysis of the key trends in each segment of the market, along with forecasts at the country and regional levels for 2026-2034. Our report has categorized the market based on specimen type, biobank type, application, and end user.
Specimen Type Insights:
Biobank Type Insights:
Application Insights:
End User Insights:
Regional Insights:
COMPETITIVE LANDSCAPE:
The market research report has also provided a comprehensive analysis of the competitive landscape. Competitive analysis such as market structure, key player positioning, top winning strategies, competitive dashboard, and company evaluation quadrant has been covered in the report. Also, detailed profiles of all major companies have been provided.
KEY QUESTIONS ANSWERED IN THIS REPORT
How has the South Korea biobanking market performed so far and how will it perform in the coming years?
What is the breakup of the South Korea biobanking market on the basis of specimen type?
What is the breakup of the South Korea biobanking market on the basis of biobank type?
What is the breakup of the South Korea biobanking market on the basis of application?
What is the breakup of the South Korea biobanking market on the basis of end user?
What is the breakup of the South Korea biobanking market on the basis of region?
What are the various stages in the value chain of the South Korea biobanking market?
What are the key driving factors and challenges in the South Korea biobanking market?
What is the structure of the South Korea biobanking market and who are the key players?
What is the degree of competition in the South Korea biobanking market?
SOUTH KOREA BIOBANKING MARKET TRENDS:
Nationwide Research Infrastructure and Policy-driven Expansion
South Korea has invested heavily in establishing nationwide biobanking networks linked to academic hospitals, research institutes, and public health agencies. These repositories store diverse biological samples, tissue, blood, and genomic data, supporting translational research, precision medicine, and drug discovery. On 28 th April 2025, the International Seabed Authority (ISA) and South Korea’s Ministry of Oceans and Fisheries signed a Letter of Cooperation during the 10th Our Ocean Conference in Busan, formalizing South Korea’s participation in the ISA Deep-Sea Biobank initiative. The initiative aims to expand global access to deep-sea biological samples and genetic data, with a focus on building research capacity, particularly for developing countries. This agreement positions South Korea as a central player in advancing marine biobanking and supports the nation’s broader strategy to lead in marine biotechnology and biodiversity conservation. The government has enacted policies mandating standardized bio-specimen collection, consent protocols, and data interoperability across institutions. Public-sector funding supports infrastructure upgrades, quality control systems, and secure IT platforms. As national projects integrate population-scale biobanks with clinical trial networks, demand for accredited sample storage and associated informatics services continues to expand. South Korea biobanking market growth is being propelled by these coordinated investments in infrastructure, professional training, and ethical governance, ensuring reliable, high-quality sample access for both local and international stakeholders.
Technological Integration and Data-Driven Expansion
The modern South Korean biobanking ecosystem is embracing automation, digital tracking, and integrated data platforms to enhance utility and scalability. Automated cold storage systems with remote environmental monitoring and backup power ensure sample integrity. Barcode and RFID systems synchronize physical sample movement with laboratory information management systems (LIMS), enabling audit trails and metadata capture. Advanced informatics platforms link biospecimen details with genomic, proteomic, and de-identified clinical data for AI-driven research. This integration supports cohort discovery, bioinformatics-driven stratification, and predictive modeling. Cybersecurity and privacy frameworks are embedded to comply with national data protection laws, enhancing trust among participants and stakeholders. As biobanks evolve from physical repositories to data-rich research assets, services such as sample processing, biomarker annotation, and analytics consulting are becoming profitable lines. On 9 th May 2024, CHA Bio Group and CIC signed an MoU to establish a Cell Gene Biobank-based Open Innovation Center (CGB) in Pangyo 2nd Techno Valley, South Korea. The facility, spanning 66,115 square meters across 14 floors, is scheduled for completion in December 2025 and will include CDMO production lines, cGMP manufacturing, and a stem cell biobank. This initiative is set to strengthen South Korea’s biobanking infrastructure by attracting biotech ventures and integrating clinical, academic, and industrial capabilities into one global biotech hub. Cross-institutional interoperability and cloud-based data sharing further strengthen collaborations, making the platform more attractive to multinational trials. The resulting digital-first transformation positions biobanks as essential infrastructure in South Korea’s bioscience innovation landscape.
SOUTH KOREA BIOBANKING MARKET SEGMENTATION:
IMARC Group provides an analysis of the key trends in each segment of the market, along with forecasts at the country and regional levels for 2026-2034. Our report has categorized the market based on specimen type, biobank type, application, and end user.
Specimen Type Insights:
- Blood Products
- Solid Tissue
- Cell Lines
- Nucleic Acid
- Others
Biobank Type Insights:
- Population-based Biobanks
- Disease-oriented Biobanks
Application Insights:
- Therapeutics
- Research
End User Insights:
- Academic Institutions
- Pharma and Biotech Companies
Regional Insights:
- Seoul Capital Area
- Yeongnam (Southeastern Region)
- Honam (Southwestern Region)
- Hoseo (Central Region)
- Others
COMPETITIVE LANDSCAPE:
The market research report has also provided a comprehensive analysis of the competitive landscape. Competitive analysis such as market structure, key player positioning, top winning strategies, competitive dashboard, and company evaluation quadrant has been covered in the report. Also, detailed profiles of all major companies have been provided.
KEY QUESTIONS ANSWERED IN THIS REPORT
How has the South Korea biobanking market performed so far and how will it perform in the coming years?
What is the breakup of the South Korea biobanking market on the basis of specimen type?
What is the breakup of the South Korea biobanking market on the basis of biobank type?
What is the breakup of the South Korea biobanking market on the basis of application?
What is the breakup of the South Korea biobanking market on the basis of end user?
What is the breakup of the South Korea biobanking market on the basis of region?
What are the various stages in the value chain of the South Korea biobanking market?
What are the key driving factors and challenges in the South Korea biobanking market?
What is the structure of the South Korea biobanking market and who are the key players?
What is the degree of competition in the South Korea biobanking market?
1 PREFACE
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 SOUTH KOREA BIOBANKING MARKET - INTRODUCTION
4.1 Overview
4.2 Market Dynamics
4.3 Industry Trends
4.4 Competitive Intelligence
5 SOUTH KOREA BIOBANKING MARKET LANDSCAPE
5.1 Historical and Current Market Trends (?2020-2025?)
5.2 Market Forecast (?2026-2034?)
6 SOUTH KOREA BIOBANKING MARKET – BREAKUP BY SPECIMEN TYPE
6.1 Blood Products
6.1.1 Overview
6.1.2 Historical and Current Market Trends (?2020-2025?)
6.1.3 Market Forecast (?2026-2034?)
6.2 Solid Tissue
6.2.1 Overview
6.2.2 Historical and Current Market Trends (?2020-2025?)
6.2.3 Market Forecast (?2026-2034?)
6.3 Cell Lines
6.3.1 Overview
6.3.2 Historical and Current Market Trends (?2020-2025?)
6.3.3 Market Forecast (?2026-2034?)
6.4 Nucleic Acid
6.4.1 Overview
6.4.2 Historical and Current Market Trends (?2020-2025?)
6.4.3 Market Forecast (?2026-2034?)
6.5 Others
6.5.1 Historical and Current Market Trends (?2020-2025?)
6.5.2 Market Forecast (?2026-2034?)
7 SOUTH KOREA BIOBANKING MARKET – BREAKUP BY BIOBANK TYPE
7.1 Population-based Biobanks
7.1.1 Overview
7.1.2 Historical and Current Market Trends (?2020-2025?)
7.1.3 Market Forecast (?2026-2034?)
7.2 Disease-oriented Biobanks
7.2.1 Overview
7.2.2 Historical and Current Market Trends (?2020-2025?)
7.2.3 Market Forecast (?2026-2034?)
8 SOUTH KOREA BIOBANKING MARKET – BREAKUP BY APPLICATION
8.1 Therapeutics
8.1.1 Overview
8.1.2 Historical and Current Market Trends (?2020-2025?)
8.1.3 Market Forecast (?2026-2034?)
8.2 Research
8.2.1 Overview
8.2.2 Historical and Current Market Trends (?2020-2025?)
8.2.3 Market Forecast (?2026-2034?)
9 SOUTH KOREA BIOBANKING MARKET – BREAKUP BY END USER
9.1 Academic Institutions
9.1.1 Overview
9.1.2 Historical and Current Market Trends (?2020-2025?)
9.1.3 Market Forecast (?2026-2034?)
9.2 Pharma and Biotech Companies
9.2.1 Overview
9.2.2 Historical and Current Market Trends (?2020-2025?)
9.2.3 Market Forecast (?2026-2034?)
10 SOUTH KOREA BIOBANKING MARKET – BREAKUP BY REGION
10.1 Seoul Capital Area
10.1.1 Overview
10.1.2 Historical and Current Market Trends (?2020-2025?)
10.1.3 Market Breakup by Specimen Type
10.1.4 Market Breakup by Biobank Type
10.1.5 Market Breakup by Application
10.1.6 Market Breakup by End User
10.1.7 Key Players
10.1.8 Market Forecast (?2026-2034?)
10.2 Yeongnam (Southeastern Region)
10.2.1 Overview
10.2.2 Historical and Current Market Trends (?2020-2025?)
10.2.3 Market Breakup by Specimen Type
10.2.4 Market Breakup by Biobank Type
10.2.5 Market Breakup by Application
10.2.6 Market Breakup by End User
10.2.7 Key Players
10.2.8 Market Forecast (?2026-2034?)
10.3 Honam (Southwestern Region)
10.3.1 Overview
10.3.2 Historical and Current Market Trends (?2020-2025?)
10.3.3 Market Breakup by Specimen Type
10.3.4 Market Breakup by Biobank Type
10.3.5 Market Breakup by Application
10.3.6 Market Breakup by End User
10.3.7 Key Players
10.3.8 Market Forecast (?2026-2034?)
10.4 Hoseo (Central Region)
10.4.1 Overview
10.4.2 Historical and Current Market Trends (?2020-2025?)
10.4.3 Market Breakup by Specimen Type
10.4.4 Market Breakup by Biobank Type
10.4.5 Market Breakup by Application
10.4.6 Market Breakup by End User
10.4.7 Key Players
10.4.8 Market Forecast (?2026-2034?)
10.5 Others
10.5.1 Historical and Current Market Trends (?2020-2025?)
10.5.2 Market Forecast (?2026-2034?)
11 SOUTH KOREA BIOBANKING MARKET – COMPETITIVE LANDSCAPE
11.1 Overview
11.2 Market Structure
11.3 Market Player Positioning
11.4 Top Winning Strategies
11.5 Competitive Dashboard
11.6 Company Evaluation Quadrant
12 PROFILES OF KEY PLAYERS
12.1 Company A
12.1.1 Business Overview
12.1.2 Products Offered
12.1.3 Business Strategies
12.1.4 SWOT Analysis
12.1.5 Major News and Events
12.2 Company B
12.2.1 Business Overview
12.2.2 Products Offered
12.2.3 Business Strategies
12.2.4 SWOT Analysis
12.2.5 Major News and Events
12.3 Company C
12.3.1 Business Overview
12.3.2 Products Offered
12.3.3 Business Strategies
12.3.4 SWOT Analysis
12.3.5 Major News and Events
12.4 Company D
12.4.1 Business Overview
12.4.2 Products Offered
12.4.3 Business Strategies
12.4.4 SWOT Analysis
12.4.5 Major News and Events
12.5 Company E
12.5.1 Business Overview
12.5.2 Products Offered
12.5.3 Business Strategies
12.5.4 SWOT Analysis
12.5.5 Major News and Events
13 SOUTH KOREA BIOBANKING MARKET - INDUSTRY ANALYSIS
13.1 Drivers, Restraints, and Opportunities
13.1.1 Overview
13.1.2 Drivers
13.1.3 Restraints
13.1.4 Opportunities
13.2 Porters Five Forces Analysis
13.2.1 Overview
13.2.2 Bargaining Power of Buyers
13.2.3 Bargaining Power of Suppliers
13.2.4 Degree of Competition
13.2.5 Threat of New Entrants
13.2.6 Threat of Substitutes
13.3 Value Chain Analysis
14 APPENDIX
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 SOUTH KOREA BIOBANKING MARKET - INTRODUCTION
4.1 Overview
4.2 Market Dynamics
4.3 Industry Trends
4.4 Competitive Intelligence
5 SOUTH KOREA BIOBANKING MARKET LANDSCAPE
5.1 Historical and Current Market Trends (?2020-2025?)
5.2 Market Forecast (?2026-2034?)
6 SOUTH KOREA BIOBANKING MARKET – BREAKUP BY SPECIMEN TYPE
6.1 Blood Products
6.1.1 Overview
6.1.2 Historical and Current Market Trends (?2020-2025?)
6.1.3 Market Forecast (?2026-2034?)
6.2 Solid Tissue
6.2.1 Overview
6.2.2 Historical and Current Market Trends (?2020-2025?)
6.2.3 Market Forecast (?2026-2034?)
6.3 Cell Lines
6.3.1 Overview
6.3.2 Historical and Current Market Trends (?2020-2025?)
6.3.3 Market Forecast (?2026-2034?)
6.4 Nucleic Acid
6.4.1 Overview
6.4.2 Historical and Current Market Trends (?2020-2025?)
6.4.3 Market Forecast (?2026-2034?)
6.5 Others
6.5.1 Historical and Current Market Trends (?2020-2025?)
6.5.2 Market Forecast (?2026-2034?)
7 SOUTH KOREA BIOBANKING MARKET – BREAKUP BY BIOBANK TYPE
7.1 Population-based Biobanks
7.1.1 Overview
7.1.2 Historical and Current Market Trends (?2020-2025?)
7.1.3 Market Forecast (?2026-2034?)
7.2 Disease-oriented Biobanks
7.2.1 Overview
7.2.2 Historical and Current Market Trends (?2020-2025?)
7.2.3 Market Forecast (?2026-2034?)
8 SOUTH KOREA BIOBANKING MARKET – BREAKUP BY APPLICATION
8.1 Therapeutics
8.1.1 Overview
8.1.2 Historical and Current Market Trends (?2020-2025?)
8.1.3 Market Forecast (?2026-2034?)
8.2 Research
8.2.1 Overview
8.2.2 Historical and Current Market Trends (?2020-2025?)
8.2.3 Market Forecast (?2026-2034?)
9 SOUTH KOREA BIOBANKING MARKET – BREAKUP BY END USER
9.1 Academic Institutions
9.1.1 Overview
9.1.2 Historical and Current Market Trends (?2020-2025?)
9.1.3 Market Forecast (?2026-2034?)
9.2 Pharma and Biotech Companies
9.2.1 Overview
9.2.2 Historical and Current Market Trends (?2020-2025?)
9.2.3 Market Forecast (?2026-2034?)
10 SOUTH KOREA BIOBANKING MARKET – BREAKUP BY REGION
10.1 Seoul Capital Area
10.1.1 Overview
10.1.2 Historical and Current Market Trends (?2020-2025?)
10.1.3 Market Breakup by Specimen Type
10.1.4 Market Breakup by Biobank Type
10.1.5 Market Breakup by Application
10.1.6 Market Breakup by End User
10.1.7 Key Players
10.1.8 Market Forecast (?2026-2034?)
10.2 Yeongnam (Southeastern Region)
10.2.1 Overview
10.2.2 Historical and Current Market Trends (?2020-2025?)
10.2.3 Market Breakup by Specimen Type
10.2.4 Market Breakup by Biobank Type
10.2.5 Market Breakup by Application
10.2.6 Market Breakup by End User
10.2.7 Key Players
10.2.8 Market Forecast (?2026-2034?)
10.3 Honam (Southwestern Region)
10.3.1 Overview
10.3.2 Historical and Current Market Trends (?2020-2025?)
10.3.3 Market Breakup by Specimen Type
10.3.4 Market Breakup by Biobank Type
10.3.5 Market Breakup by Application
10.3.6 Market Breakup by End User
10.3.7 Key Players
10.3.8 Market Forecast (?2026-2034?)
10.4 Hoseo (Central Region)
10.4.1 Overview
10.4.2 Historical and Current Market Trends (?2020-2025?)
10.4.3 Market Breakup by Specimen Type
10.4.4 Market Breakup by Biobank Type
10.4.5 Market Breakup by Application
10.4.6 Market Breakup by End User
10.4.7 Key Players
10.4.8 Market Forecast (?2026-2034?)
10.5 Others
10.5.1 Historical and Current Market Trends (?2020-2025?)
10.5.2 Market Forecast (?2026-2034?)
11 SOUTH KOREA BIOBANKING MARKET – COMPETITIVE LANDSCAPE
11.1 Overview
11.2 Market Structure
11.3 Market Player Positioning
11.4 Top Winning Strategies
11.5 Competitive Dashboard
11.6 Company Evaluation Quadrant
12 PROFILES OF KEY PLAYERS
12.1 Company A
12.1.1 Business Overview
12.1.2 Products Offered
12.1.3 Business Strategies
12.1.4 SWOT Analysis
12.1.5 Major News and Events
12.2 Company B
12.2.1 Business Overview
12.2.2 Products Offered
12.2.3 Business Strategies
12.2.4 SWOT Analysis
12.2.5 Major News and Events
12.3 Company C
12.3.1 Business Overview
12.3.2 Products Offered
12.3.3 Business Strategies
12.3.4 SWOT Analysis
12.3.5 Major News and Events
12.4 Company D
12.4.1 Business Overview
12.4.2 Products Offered
12.4.3 Business Strategies
12.4.4 SWOT Analysis
12.4.5 Major News and Events
12.5 Company E
12.5.1 Business Overview
12.5.2 Products Offered
12.5.3 Business Strategies
12.5.4 SWOT Analysis
12.5.5 Major News and Events
13 SOUTH KOREA BIOBANKING MARKET - INDUSTRY ANALYSIS
13.1 Drivers, Restraints, and Opportunities
13.1.1 Overview
13.1.2 Drivers
13.1.3 Restraints
13.1.4 Opportunities
13.2 Porters Five Forces Analysis
13.2.1 Overview
13.2.2 Bargaining Power of Buyers
13.2.3 Bargaining Power of Suppliers
13.2.4 Degree of Competition
13.2.5 Threat of New Entrants
13.2.6 Threat of Substitutes
13.3 Value Chain Analysis
14 APPENDIX
